Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/22/Suppl_8/viii40/601436/mdr470.pdf
Reference29 articles.
1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009
2. Reactivity of a monoclonal antibody with human ovarian carcinoma;Bast;J Clin Invest,1981
3. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer;Rustin;Clin Cancer Res,2004
4. New guidelines to evaluate the response to treatment in solid tumors;Therasse;J Natl Cancer Inst,2000
5. Selection of active drugs for ovarian cancer based on CA 125 and standard response rates to phase II trials;Rustin;J Clin Oncol,2000
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis;JNCI Cancer Spectrum;2023-05-27
2. Cancer Biomarkers: Status and Its Future Direction;Indian Journal of Surgery;2023-02-20
3. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy;International Journal of Gynecologic Cancer;2023-01-27
4. Translational Opportunities of Extracellular Vesicles in Biomedicine;Circulating Tumor Cells;2023
5. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125;European Radiology;2021-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3